|
1
|
Anderson CD, Pinson CW, Berlin J and Chari
RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist.
9:43–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Howlader N, Noone AM and Krapcho M: SEER
Cancer Statistics Review 1975–2008. National Cancer Institute;
Bethesda, MD: 2018
|
|
3
|
Toyoda M, Ajiki T, Fujiwara Y, Nagano H,
Kobayashi S, Sakai D, Hatano E, Kanai M, Nakamori S, Miyamoto A, et
al: Phase I study of adjuvant chemotherapy with gemcitabine plus
cisplatin in patients with biliary tract cancer undergoing curative
resection without major hepatectomy (KHBO1004). Cancer Chemother
Pharmacol. 73:1295–1301. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colvin H, Mizushima T, Eguchi H, Takiguchi
S, Doki Y and Mori M: Gastroenterological surgery in Japan: The
past, the present and the future. Ann Gastroenterol Surg. 1:5–10.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyakawa S, Ishihara S, Horiguchi A,
Takada T, Miyazaki M and Nagakawa T: Biliary tract cancer
treatment: 5,584 results from the Biliary Tract Cancer Statistics
Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg.
16:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wellner UF, Shen Y, Keck T, Jin W and Xu
Z: The survival outcome and prognostic factors for distal
cholangiocarcinoma following surgical resection: A meta-analysis
for the 5-year survival. Surg Today. 47:271–279. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Higuchi R, Ota T, Yazawa T, Kajiyama H,
Araida T, Furukawa T, Yoshikawa T, Takasaki K and Yamamoto M:
Improved surgical outcomes for hilar cholangiocarcinoma: Changes in
surgical procedures and related outcomes based on 40 years of
experience at a single institution. Surg Today. 46:74–83. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kobayashi S, Miyamoto A, Shimizu J,
Kashiwazaki M, Takeda Y, Ueshima S, Kim Y, Kitagawa T, Dono K, Mori
M, et al: Comparison of 4-weekly vs 3-weekly gemcitabine as
adjuvant chemotherapy following curative resection for biliary
tract cancer: A prospective randomized controlled trial. J Cancer
Ther. 02:703–709. 2011. View Article : Google Scholar
|
|
9
|
Kobayashi S, Nagano H, Sakai D, Eguchi H,
Hatano E, Kanai M, Seo S, Taura K, Fujiwara Y, Ajiki T, et al:
Phase I study of adjuvant gemcitabine or S-1 in patients with
biliary tract cancers undergoing major hepatectomy: KHBO1003 study.
Cancer Chemother Pharmacol. 74:699–709. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mizuno T, Ebata T, Yokoyama Y, Igami T,
Sugawara G, Yamaguchi J and Nagino M: Adjuvant gemcitabine
monotherapy for resectable perihilar cholangiocarcinoma with lymph
node involvement: A propensity score matching analysis. Surg Today.
47:182–192. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen Q, Dai Z, Yin D, Yang LX, Wang Z,
Xiao YS, Fan J and Zhou J: Negative impact of preoperative
platelet-lymphocyte ratio on outcome after hepatic resection for
intrahepatic cholangiocarcinoma. Medicine (Baltimore). 94:e5742015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gomez D, Morris-Stiff G, Toogood GJ, Lodge
JP and Prasad KR: Impact of systemic inflammation on outcome
following resection for intrahepatic cholangiocarcinoma. J Surg
Oncol. 97:513–518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang C, Wang H, Ning Z, Xu L, Zhuang L,
Wang P and Meng Z: Prognostic nutritional index serves as a
predictive marker of survival and associates with systemic
inflammatory response in metastatic intrahepatic
cholangiocarcinoma. OncoTargets Ther. 9:6417–6423. 2016. View Article : Google Scholar
|
|
14
|
Tibau A, Ennis M and Goodwin PJ:
Post-surgical highly sensitive C-reactive protein and prognosis in
early-stage breast cancer. Breast Cancer Res Treat. 141:485–493.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saito T, Kurokawa Y, Miyazaki Y, Makino T,
Takahashi T, Yamasaki M, Nakajima K, Takiguchi S, Mori M and Doki
Y: Which is a more reliable indicator of survival after gastric
cancer surgery: Postoperative complication occurrence or C-reactive
protein elevation? J Surg Oncol. 112:894–899. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu Y, Huang S, Li P, Chen B, Liu W, Chen Z
and Yin F: Prognostic evaluation of preoperative serum C-reactive
protein concentration in patients with epithelial ovarian cancer.
Exp Ther Med. 9:2003–2007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujiwara Y, Shiba H, Furukawa K, Iida T,
Sakamoto T, Gocho T, Wakiyama S, Hirohara S, Ishida Y, Misawa T, et
al: Perioperative change in white blood cell count predicts outcome
of hepatic resection for hepatocellular carcinoma. J Hepatobiliary
Pancreat Sci. 17:892–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shiba H, Furukawa K, Fujiwara Y, Futagawa
Y, Haruki K, Wakiyama S, Ishida Y, Misawa T and Yanaga K:
Postoperative peak serum C-reactive protein predicts outcome of
hepatic resection for hepatocellular carcinoma. Anticancer Res.
33:705–709. 2013.PubMed/NCBI
|
|
19
|
Japanese Society of
Hepato-Biliary-Pancreatic Surgery, . General Rules for Clinical and
Pathological Studies on Cancer of the Biliary Tract. 6th. Kanehara
and Co., Ltd.; Tokyo: 2013
|
|
20
|
Liver Cancer Study Group of Japan, .
General Rules for the Clinical and Pathological Study of Primary
Liver Cancer. 6th. Kanehara and Co., Ltd.; Tokyo: 2015
|
|
21
|
Ando T, Ito H, Kanbe A, Hara A and
Seishima M: Deficiency of NALP3 Signaling Impairs Liver
Regeneration After Partial Hepatectomy. Inflammation. 40:1717–1725.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamada D, Rizvi S, Razumilava N, Bronk SF,
Davila JI, Champion MD, Borad MJ, Bezerra JA, Chen X and Gores GJ:
IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an
interleukin-6-sensitive mechanism. Hepatology. 61:1627–1642. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamada D, Kobayashi S, Wada H, Kawamoto K,
Marubashi S, Eguchi H, Ishii H, Nagano H, Doki Y and Mori M: Role
of crosstalk between interleukin-6 and transforming growth
factor-beta 1 in epithelial-mesenchymal transition and
chemoresistance in biliary tract cancer. Eur J Cancer.
49:1725–1740. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sakamoto T, Kobayashi S, Yamada D, Nagano
H, Tomokuni A, Tomimaru Y, Noda T, Gotoh K, Asaoka T, Wada H, et
al: A histone deacetylase inhibitor suppresses
epithelial-mesenchymal transition and attenuates chemoresistance in
biliary tract cancer. PLoS One. 11:e01459852016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kobayashi S, Werneburg NW, Bronk SF,
Kaufmann SH and Gores GJ: Interleukin-6 contributes to Mcl-1
up-regulation and TRAIL resistance via an Akt-signaling pathway in
cholangiocarcinoma cells. Gastroenterology. 128:2054–2065. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamada D, Kobayashi S, Yamamoto H,
Tomimaru Y, Noda T, Uemura M, Wada H, Marubashi S, Eguchi H,
Tanemura M, et al: Role of the hypoxia-related gene, JMJD1A, in
hepatocellular carcinoma: Clinical impact on recurrence after
hepatic resection. Ann Surg Oncol. 19 (Suppl 3):S355–S364. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ibuki Y, Hamai Y, Hihara J, Emi M, Taomoto
J, Furukawa T, Yamakita I, Kurokawa T and Okada M: Role of
postoperative C-reactive protein levels in predicting prognosis
After surgical treatment of esophageal cancer. World J Surg.
41:1558–1565. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Trellakis S, Bruderek K, Dumitru CA,
Gholaman H, Gu X, Bankfalvi A, Scherag A, Hütte J, Dominas N,
Lehnerdt GF, et al: Polymorphonuclear granulocytes in human head
and neck cancer: Enhanced inflammatory activity, modulation by
cancer cells and expansion in advanced disease. Int J Cancer.
129:2183–2193. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schmidt H, Bastholt L, Geertsen P,
Christensen IJ, Larsen S, Gehl J and von der Maase H: Elevated
neutrophil and monocyte counts in peripheral blood are associated
with poor survival in patients with metastatic melanoma: A
prognostic model. Br J Cancer. 93:273–278. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Uribe-Querol E and Rosales C: Neutrophils
in cancer: Two sides of the same coin. J Immunol Res.
2015:9836982015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wislez M, Rabbe N, Marchal J, Milleron B,
Crestani B, Mayaud C, Antoine M, Soler P and Cadranel J: Hepatocyte
growth factor production by neutrophils infiltrating
bronchioloalveolar subtype pulmonary adenocarcinoma: Role in tumor
progression and death. Cancer Res. 63:1405–1412. 2003.PubMed/NCBI
|
|
32
|
Jensen HK, Donskov F, Marcussen N,
Nordsmark M, Lundbeck F and von der Maase H: Presence of
intratumoral neutrophils is an independent prognostic factor in
localized renal cell carcinoma. J Clin Oncol. 27:4709–4717. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cata JP, Velasquez JF, Ramirez MF, Vauthey
JN, Gottumukkala V, Conrad C, Kim BJ and Aloia T: Inflammation and
pro-resolution inflammation after hepatobiliary surgery. World J
Surg Oncol. 15:1522017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Alazawi W, Pirmadjid N, Lahiri R and
Bhattacharya S: Inflammatory and immune responses to surgery and
their clinical impact. Ann Surg. 264:73–80. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fujii M, Yamashita T, Ishiguro R, Tashiro
M and Kameyama K: Significance of epidermal growth factor receptor
and tumor associated tissue eosinophilia in the prognosis of
patients with nasopharyngeal carcinoma. Auris Nasus Larynx.
29:175–181. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nielsen HJ, Hansen U, Christensen IJ,
Reimert CM, Bru N and Moesgaard F: Independent prognostic value of
eosinophil and mast cell infiltration in colorectal cancer tissue.
J Pathol. 189:487–495. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jain M, Kasetty S, Sudheendra US, Tijare
M, Khan S and Desai A: Assessment of tissue eosinophilia as a
prognosticator in oral epithelial dysplasia and oral squamous cell
carcinoma-an image analysis study. Pathol Res Int. 2014:5075122014.
View Article : Google Scholar
|
|
39
|
McNeel DG, Gardner TA, Higano CS, Kantoff
PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA and Dreicer
R: A transient increase in eosinophils is associated with prolonged
survival in men with metastatic castration-resistant prostate
cancer who receive sipuleucel-T. Cancer Immunol Res. 2:988–999.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yalcin AD, Kargi A and Gumuslu S: Blood
eosinophil and platelet levels, proteomics patterns of trail and
CXCL8 correlated with survival in bevacizumab treated metastatic
colon cancers. Clin Lab. 60:339–340. 2014.PubMed/NCBI
|
|
41
|
Tjota MY, Williams JW, Lu T, Clay BS, Byrd
T, Hrusch CL, Decker DC, de Araujo CA, Bryce PJ and Sperling AI:
IL-33-dependent induction of allergic lung inflammation by FcγRIII
signaling. J Clin Invest. 123:2287–2297. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Stolarski B, Kurowska-Stolarska M, Kewin
P, Xu D and Liew FY: IL-33 exacerbates eosinophil-mediated airway
inflammation. J Immunol. 185:3472–3480. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dyer KD, Percopo CM and Rosenberg HF:
IL-33 promotes eosinophilia in vivo and antagonizes IL-5-dependent
eosinophil hematopoiesis ex vivo. Immunol Lett. 150:41–47. 2013.
View Article : Google Scholar : PubMed/NCBI
|
